Predominant Expression of Fas (CD95) Ligand in Metastatic Melanoma Revealed by Longitudinal Analysis
- 1 June 1999
- journal article
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 112 (6), 899-902
- https://doi.org/10.1046/j.1523-1747.1999.00607.x
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Lymphocyte apoptosis induced by Fas ligand- expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes.Journal of Clinical Investigation, 1998
- Lymphocyte apoptosis induced by CD95 (APO–1/Fas) ligand–expressing tumor cells — A mechanism of immune evasion?Nature Medicine, 1996
- Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune EscapeScience, 1996
- Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils.The Journal of Experimental Medicine, 1996
- CD95-Induced Apoptosis of Lymphocytes in an Immune Privileged Site Induces Immunological ToleranceImmunity, 1996
- Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanomaCancer, 1996
- Fas ligand in human serumNature Medicine, 1996
- Fas and FasL in the homeostatic regulation of immune responsesImmunology Today, 1995
- Fas ligand mediates activation-induced cell death in human T lymphocytes.The Journal of Experimental Medicine, 1995
- Fas and Fas Ligand: A Death Factor and Its ReceptorAdvances in Immunology, 1994